CLINICAL BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN CERVICAL CANCER ACROSS FIVE HIGH-BURDEN ASIA-PACIFIC COUNTRIES: A TARGETED LITERATURE REVIEW...
Author(s)
Ranjani Durga Devarapalli, M. Pharm1, Manasa Vishnubhotla, M. Pharm1, Mahendra Kumar Rai, PhD2.
1Trinity Life Sciences, Mumbai, India, 2Trinity Lifesciences, Singapore, Singapore.
1Trinity Life Sciences, Mumbai, India, 2Trinity Lifesciences, Singapore, Singapore.
OBJECTIVES: Cervical cancer remains a leading cause of cancer-related morbidity and mortality among women, with a disproportionate burden in Asia-Pacific region. This targeted literature review (TLR) synthesized evidence on clinical burden and health-related quality of life (HRQoL) in women with cervical cancer across India, China, Indonesia, Japan, and South Korea.
METHODS: A TLR was conducted in PubMed, Embase, and Google Scholar for studies published between January 2010 and April 2026, following PRISMA 2020 reporting standards. Search terms covered cervical cancer, clinical burden (incidence, mortality, prevalence, survival), and HRQoL instruments (EQ-5D, EORTC QLQ-C30/CX24). Records were screened and data extracted as per predefined eligibility criteria. Study quality was assessed using standard risk-of-bias tools, and evidence was synthesized descriptively given the heterogeneity across populations and designs.
RESULTS: Thirty-two studies were included. In 2022, the highest disease burden was reported in China (155,700 cases; 55,700 deaths) and India (127,526 cases; 79,906 deaths), followed by Indonesia and Japan. Chinese incidence increased from 16.74 to 19.76 per 100,000 between 1990 and 2021, whereas South Korea showed declining incidence (32.8 to 15.9 per 100,000) and mortality (5.2 to 2.1 per 100,000). The pooled 5-year survival rate was 62.34% (95% CI: 58.10-66.59). HRQoL declined with disease progression across settings. EQ-5D-5L utility scores ranged from 0.64 in India to 0.71-0.85 across stages in Indonesia. Pain/discomfort (67.8%) and anxiety/depression (57.5%) were the most frequently reported issues. In South Korea, utility scores declined from 0.93 in precancerous states to 0.78 in recurrent disease. In China, socioeconomic status and multimodality treatment were primary drivers of HRQoL impairment.
CONCLUSIONS: Cervical cancer imposes a substantial clinical and humanistic burden across Asia-Pacific countries, characterized by heterogeneous epidemiological trends, variable survival outcomes, and consistent deterioration in HRQoL with disease progression. These findings support the integration of HRQoL evidence with clinical outcomes to inform screening strategies, treatment decisions, and health policy.
METHODS: A TLR was conducted in PubMed, Embase, and Google Scholar for studies published between January 2010 and April 2026, following PRISMA 2020 reporting standards. Search terms covered cervical cancer, clinical burden (incidence, mortality, prevalence, survival), and HRQoL instruments (EQ-5D, EORTC QLQ-C30/CX24). Records were screened and data extracted as per predefined eligibility criteria. Study quality was assessed using standard risk-of-bias tools, and evidence was synthesized descriptively given the heterogeneity across populations and designs.
RESULTS: Thirty-two studies were included. In 2022, the highest disease burden was reported in China (155,700 cases; 55,700 deaths) and India (127,526 cases; 79,906 deaths), followed by Indonesia and Japan. Chinese incidence increased from 16.74 to 19.76 per 100,000 between 1990 and 2021, whereas South Korea showed declining incidence (32.8 to 15.9 per 100,000) and mortality (5.2 to 2.1 per 100,000). The pooled 5-year survival rate was 62.34% (95% CI: 58.10-66.59). HRQoL declined with disease progression across settings. EQ-5D-5L utility scores ranged from 0.64 in India to 0.71-0.85 across stages in Indonesia. Pain/discomfort (67.8%) and anxiety/depression (57.5%) were the most frequently reported issues. In South Korea, utility scores declined from 0.93 in precancerous states to 0.78 in recurrent disease. In China, socioeconomic status and multimodality treatment were primary drivers of HRQoL impairment.
CONCLUSIONS: Cervical cancer imposes a substantial clinical and humanistic burden across Asia-Pacific countries, characterized by heterogeneous epidemiological trends, variable survival outcomes, and consistent deterioration in HRQoL with disease progression. These findings support the integration of HRQoL evidence with clinical outcomes to inform screening strategies, treatment decisions, and health policy.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
EPH30
Topic
Epidemiology & Public Health
Disease
SDC: Oncology